- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02303860
Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)
Pharmacokinetic Study of ORM-12741 After Multiple Oral Doses
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Turku, Finland, 02520
- Clinical Research Services Turku - CRST Oy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent (IC) obtained.
- Good general health ascertained by detailed medical history and physical examination.
- Females and males between 18 and 65 years of age (inclusive).
- Body mass index (BMI) between 18-30 kg/m2 (inclusive, BMI = weight/height2).
- Weight 50-100 kg (inclusive).
- Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or other intestinal problems).
Exclusion Criteria:
- Predicted poor compliance or inability to communicate well with the investigator or the study centre personnel.
- Veins unsuitable for repeated venipuncture or cannulation.
- Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator.
- Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. Hormonal contraception and hormone replacement therapy are allowed.
- Susceptibility to severe allergic reactions.
- Intake of any medication that could affect the outcome of the study, within 2 weeks prior to the first study treatment administration or less than 5 times the half-life of the medication. Possible enzyme inducing drugs will be discussed case-by-case with the sponsor.
- Regular consumption of more than 21 units of alcohol per week for males and 16 units per week for females (1 unit = 4 cl spirits, about 13 g of alcohol).
- Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.
- Inability to refrain from using nicotine-containing products during the stay at the study centre.
- Inability to refrain from consuming caffeine-containing beverages during the stay at the study centre, e.g. propensity to develop headaches when refraining from caffeine-containing beverages.
- Blood donation or loss of significant amount of blood within 3 months prior to the first study treatment administration.
Any clinically significant 12-lead electrocardiogram (ECG) abnormality after 10-minute rest in supine position at the screening visit, as judged by the investigator. For example:
- QTc (calculated with the Bazett's formula) > 470 msec for females and 450 msec for men.
- HR < 45 beats/minute or > 100 beats/minute after a 10-minute rest in supine position at the screening visit.
At the screening visit systolic blood pressure (BP) < 90 mmHg or > 150 mmHg after a 10- minute rest in supine position, diastolic BP < 50 mmHg or > 90 mmHg after a 10-minute rest in supine position, or symptomatic orthostatic hypotension, or
- decrease of ≥ 20 mmHg of systolic BP or
- decrease of ≥ 10 mmHg of diastolic BP after 3 minutes in standing position.
- Any abnormal value in laboratory tests, or vital signs, or physical examination finding, which in the opinion of the investigator could interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.
- History of drug abuse or positive result in drug abuse test.
- Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).
- Females of childbearing potential if they are not using proper contraception (hormonal contraception, intrauterine device [IUD] or surgical sterilization, spermicidal foam in conjunction with condom on male partner) during the study. Use of oral/hormonal contraception alone is not acceptable. (Note: women of childbearing potential with no current heterosexual relationship can be included without contraception according to the judgement of the investigator).
- Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the study subject.
- Participation in a clinical drug study within 3 months prior to the first study treatment administration of this study or earlier participation in a clinical study with ORM-12741.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Panel 1
Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
|
Modified release formulation of ORM-12741
Modified release formulation of ORM-12741
Immediately release formulation of ORM-12741
|
EXPERIMENTAL: Panel 2
Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
|
Modified release formulation of ORM-12741
Modified release formulation of ORM-12741
Immediately release formulation of ORM-12741
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax, Tmax, AUC, T1/2
Time Frame: Blood samples collected once at day 2, 4, 6, 9, 10 and 11; twice on day 8 and frequently on day 7.
|
Pharmacokinetics
|
Blood samples collected once at day 2, 4, 6, 9, 10 and 11; twice on day 8 and frequently on day 7.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - adverse events, vital signs, ECG, safety laboratory values
Time Frame: 8 days per treatment period
|
Adverse events, vital signs, ECG, safety labs
|
8 days per treatment period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mika Scheinin, MD, Clinical Research Services Turku - CRST Oy
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 3098013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on ORM-12741 MR A
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompletedAlzheimer's DiseaseFinland
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaJanssen PharmaceuticalsCompletedAlzheimer's DiseaseFinland
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompletedHealthy Male VolunteersNetherlands
-
Orion Corporation, Orion PharmaCompleted